<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[CYNAERA]]></title><description><![CDATA[CYNAERA is an intelligence infrastructure company enabling enterprise integration across healthcare, government, and resilience systems.]]></description><link>https://www.cynaera.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Fri, 03 Apr 2026 21:19:42 GMT</lastBuildDate><atom:link href="https://www.cynaera.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[CRISPR Cell Therapy for Type 1 Diabetes: Beyond Immune Evasion Using Flare -Aware &#38; Environmental Modeling for Durable Remission]]></title><description><![CDATA[CRISPR cell therapy for type 1 diabetes is advancing toward remission, but immune-evasive beta cells alone are not enough. This paper introduces flare-aware and environmental modeling as critical factors for durable remission, improving clinical trial interpretation, therapeutic durability, and real-world outcomes.]]></description><link>https://www.cynaera.com/post/crispr-type-1-diabetes</link><guid isPermaLink="false">69cd334955ae1fb580a47757</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[White Paper]]></category><pubDate>Thu, 02 Apr 2026 21:54:05 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_3fb03e1ee7fa41d0a2fb9b587d420913~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Pediatric Long COVID: A Public Health Crisis Demanding Recognition]]></title><description><![CDATA[Pediatric Long COVID in the U.S. may affect 6–10 million children. This analysis explores prevalence, symptoms, underdiagnosis, and public health implications using US-CCUC modeling.]]></description><link>https://www.cynaera.com/post/pediatric-lc</link><guid isPermaLink="false">69ce8d6bd6854e26a0aa7960</guid><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[Healthcare Innovations]]></category><pubDate>Thu, 02 Apr 2026 18:52:05 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_d102d6b762264be1ac6ad08872ef5dd0~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Enhancing CRISPR Safety in Sickle Cell Disease Using CYNAERA Methods]]></title><description><![CDATA[CYNAERA introduces a terrain-responsive CRISPR safety framework for sickle cell disease, integrating AI-driven targeting, timing optimization, and simulation modeling to reduce risk, lower costs, and enable scalable, equitable gene therapy deployment across complex chronic conditions.]]></description><link>https://www.cynaera.com/post/crispr-sickle-cell</link><guid isPermaLink="false">69c2ab78b1bfd68174decd5e</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[Philanthropic Tools]]></category><pubDate>Tue, 24 Mar 2026 17:47:55 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_8961b3b69bb9499c8248513129fff8de~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[What Changes in Your Child’s Gaming May Be Telling You]]></title><description><![CDATA[Parents often notice changes in gaming before anyone else notices changes in health. A child who once enjoyed fast, demanding games may suddenly avoid them. Another may become intensely focused on one specific game or routine. Some children begin choosing calmer, slower, or more predictable games that simply feel better, even if they cannot explain why. This may be early clues inside a very large and still underrecognized pediatric infection-associated chronic illness.]]></description><link>https://www.cynaera.com/post/iacc-kids-gaming</link><guid isPermaLink="false">69b592e75f6a1e874c5745f5</guid><category><![CDATA[Philanthropic Tools]]></category><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[Data Ethics]]></category><pubDate>Sat, 14 Mar 2026 19:41:08 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_9c29fce23c584c70a3cd94b5101ebc9a~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Microdosing Air™ : Rebuilding Environmental Tolerance in Long COVID, ME/CFS, Dysautonomia, and Mast Cell Disorders]]></title><description><![CDATA[One of the most consistent patterns observed across infection-associated chronic conditions is heightened environmental sensitivity. Patients with Long COVID, ME/CFS, dysautonomia, and mast cell activation disorders frequently report symptom flares triggered by airborne exposures such as mold spores, fragrances, volatile organic compounds (VOCs), particulate pollution, and atmospheric changes including humidity shifts or ozone spikes.]]></description><link>https://www.cynaera.com/post/microdosing-air</link><guid isPermaLink="false">69b0810ba547e1dd3d7dd0a9</guid><category><![CDATA[White Paper]]></category><category><![CDATA[Healthcare Innovations]]></category><pubDate>Tue, 10 Mar 2026 23:26:17 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_d85db6452473427a815728abc90f99b9~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Mold Exposure as a Flare Amplifier in ME/CFS]]></title><description><![CDATA[For many people living with ME/CFS,  myself included, mold exposures contribute to flare instability, worsening fatigue, cognitive dysfunction, headaches, autonomic disruption, and reduced functional capacity. What appears to be a sudden symptom crash may, in many cases, reflect the interaction between chronic illness and a destabilizing indoor environment.]]></description><link>https://www.cynaera.com/post/mecfs-mold</link><guid isPermaLink="false">69af05146b9018dbd070b615</guid><category><![CDATA[White Paper]]></category><category><![CDATA[Public Policy]]></category><pubDate>Mon, 09 Mar 2026 20:22:13 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_0c6f05d889db444e87e0f621352c6427~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[One New Long COVID Case Every Minute in the United States]]></title><description><![CDATA[CYNAERA Institute analysis estimates roughly one new Long COVID case every minute in the United States. The model reconstructs national incidence using CDC hospitalization surveillance and reinfection-era risk estimates.]]></description><link>https://www.cynaera.com/post/one-a-minute</link><guid isPermaLink="false">69ae14fa053d59350a125d5e</guid><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><pubDate>Mon, 09 Mar 2026 12:14:01 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_a81f71bebc084f86a40b9dbb572d3bcc~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[The Hidden Public Health Cost of AI Data Centers]]></title><description><![CDATA[AI-driven environmental amplification interacts with a large and growing population of individuals with infection-associated chronic conditions (e.g., Long COVID, ME/CFS), who exhibit heightened physiological sensitivity to environmental triggers such as fine particulate matter (PM₂.₅), heat stress, and atmospheric instability. 
If you want an alternate tone that leans slightly more policy-facing:]]></description><link>https://www.cynaera.com/post/ai-data-centers</link><guid isPermaLink="false">69acdd16d66894c6d6f78ba5</guid><category><![CDATA[Public Policy]]></category><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Public Infrastructure]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[AI Strategy]]></category><pubDate>Sun, 08 Mar 2026 15:33:45 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_e7203b9edf4045abb2442e95f5c2eb0a~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[FEMA Wildfire Response Addendum Protocols for IACC (2025-2026)]]></title><description><![CDATA[Climate accelerated wildfires, burning over 7.7 million acres in 2020–2021, threaten the 65–75 million Americans with Infection-Associated Chronic Conditions (IACCs), including Long COVID, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Postural Orthostatic Tachycardia Syndrome (POTS), Mast Cell Activation Syndrome (MCAS), and Small Fiber Neuropathy (SFN) 
If you want an alternate tone that leans slightly more policy-facing:]]></description><link>https://www.cynaera.com/post/fema-wildfire</link><guid isPermaLink="false">69acc33229fc34c42794c1a8</guid><category><![CDATA[Public Infrastructure]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[Healthcare Innovations]]></category><pubDate>Sun, 08 Mar 2026 02:19:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_9f1ae73f55b343e0860918bcc838b141~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[The Moral Adinig Method™: A Framework for Harm-Aware AI Learning]]></title><description><![CDATA[The Moral Adinig Method™ is a harm-aware AI training framework that embeds contextual reasoning, moral memory, and relational identity scaffolding to improve safety and reliability. Cross-model evaluations show reduced harmful recommendations, stronger bias translation into protective guidance, and improved decision integrity in complex, high-risk environments without modifying model weights.

If you want an alternate tone that leans slightly more policy-facing:]]></description><link>https://www.cynaera.com/post/moral-adinig-method</link><guid isPermaLink="false">69a324199d34acb7c436f651</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Philanthropic Tools]]></category><category><![CDATA[AI Strategy]]></category><category><![CDATA[White Paper]]></category><pubDate>Sat, 28 Feb 2026 19:01:43 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_fe47953b23a44beaa1a18665bc1b52e2~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Aligned Intelligence Method (AIM™)]]></title><description><![CDATA[The Aligned Intelligence Method (AIM™) is a human-readable, machine-interpretable knowledge framework that embeds interpretive guardrails directly into source documents. AIM aligns lived patterns, longitudinal data, domain reasoning, and environmental context into unified analytic references that support both human understanding and consistent AI interpretation. ]]></description><link>https://www.cynaera.com/post/the-aim</link><guid isPermaLink="false">699373ab6afbe985b7a3ee07</guid><category><![CDATA[AI Strategy]]></category><category><![CDATA[Data Ethics]]></category><category><![CDATA[Public Policy]]></category><pubDate>Mon, 16 Feb 2026 20:45:38 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_f0262b6f33da4c37bfe7fb8f125b558a~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Autoimmune Disease: Patterns, Timing, and the Cost of Snapshot Diagnosis]]></title><description><![CDATA[Autoimmune and immune-mediated illness rarely begins with a clear diagnosis. More often, it begins with patterns that repeat long before medicine assigns a label. Symptoms rise, fall, and cluster. Tests come back “normal.” Patients are told to wait, monitor, or manage symptoms. Yet the immune system is already behaving abnormally. This paper refers to that early, overlooked phase as Stage Zero autoimmune illness.]]></description><link>https://www.cynaera.com/post/autoimmune-data</link><guid isPermaLink="false">6961134b7b8171b5141a06dc</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[Public Infrastructure]]></category><category><![CDATA[AI Strategy]]></category><pubDate>Fri, 09 Jan 2026 16:10:55 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_9f8499d3540a4cd0a2e65702a960a45f~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[The Antiviral Pairing Logic (APL) Framework: Terrain Stabilization with Antiviral Clearance for  Long COVID Remission]]></title><description><![CDATA[The Antiviral Pairing Logic framework synthesizes longitudinal field analysis across more than two hundred patient trajectories with in silico terrain modeling and real-world pharmacology. Durable response consistently follows three preconditions: immune stabilization to prevent cytokine rebound, mast cell and autonomic modulation before viral clearance, and energy and vascular repair after antigen reduction. ]]></description><link>https://www.cynaera.com/post/apl-framework</link><guid isPermaLink="false">6915f1e320e2491209ff403f</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[AI Strategy]]></category><pubDate>Thu, 13 Nov 2025 16:11:30 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_5d3bd73422514268b707842cfc2b4c66~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Intimate Partner Violence Risk in Infection-Associated Chronic Conditions: The RAVYNS™ Projection Model]]></title><description><![CDATA[RAVYNS™ estimates how harm becomes invisible through coerced yielding, systemic neglect, and deliberate sabotage, translating survivor intuition into measurable evidence]]></description><link>https://www.cynaera.com/post/ravyns</link><guid isPermaLink="false">6902c9ac10878d6d879e439c</guid><category><![CDATA[Public Policy]]></category><category><![CDATA[Data Ethics]]></category><category><![CDATA[White Paper]]></category><category><![CDATA[Philanthropic Tools]]></category><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Public Infrastructure]]></category><pubDate>Thu, 30 Oct 2025 04:14:37 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_d8aa5b530b704bdbaac700d5baf38389~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Pandemics to Prevention: CRATE™ - AI Enabled Cancer Surveillance ]]></title><description><![CDATA[The COVID-19 pandemic has added another layer of immune instability through persistent inflammation, viral reactivations, and population-wide biologic stress . CRATE™ converts these complex dynamics into actionable modeling signals to inform future prevention strategy]]></description><link>https://www.cynaera.com/post/crate</link><guid isPermaLink="false">68e84bbfa5a8e77456df9aa2</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Public Infrastructure]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><pubDate>Fri, 17 Oct 2025 08:51:05 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_874247b18b86450d92d79889b12dbc83~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Corrected National Prevalence Estimates for Infection-Associated Chronic Conditions (IACCs)]]></title><description><![CDATA[When corrected through the US-CCUC™ framework, the combined burden of the ten most prominent infection-associated chronic conditions is estimated to affect approximately 75–90 million Americans, with 25–35 million individuals experiencing multiple overlapping conditions. Long COVID alone likely affects a population approaching 65 million adults over time when accounting for diagnostic undercounting and relapsing disease trajectories.]]></description><link>https://www.cynaera.com/post/iacc-prevalence-us</link><guid isPermaLink="false">68b1f403a87801a237172815</guid><category><![CDATA[Public Policy]]></category><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[White Paper]]></category><pubDate>Fri, 29 Aug 2025 19:12:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_717bb5bce44544b395e7deea65737f61~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Undercounted from Kabul to Kansas: The Hidden Men of IACC]]></title><description><![CDATA[The Cultural Gendered Patriarchy Index (CGPI), developed by CYNAERA (2025), is the first cross-national system designed to quantify the effect of patriarchy on male diagnostic rates. By integrating data from 180 countries—including global gender indices, masculinity scales, health-seeking behavior datasets, and IACC prevalence studies—we reveal that millions of men are statistically invisible.]]></description><link>https://www.cynaera.com/post/iacc-men</link><guid isPermaLink="false">68ae57486e26accbc6ce4362</guid><category><![CDATA[White Paper]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[Healthcare Innovations]]></category><pubDate>Wed, 27 Aug 2025 02:20:39 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_51fa4dc92ee84b9b814d68b7affc884d~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[SPARC™: A Precision Framework for Patient Stratification in Complex Chronic Conditions]]></title><description><![CDATA[Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.]]></description><link>https://www.cynaera.com/post/sparc</link><guid isPermaLink="false">6891287cb00b0ea0c74afa03</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[AI Strategy]]></category><category><![CDATA[Public Infrastructure]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><pubDate>Tue, 05 Aug 2025 04:09:45 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_415ec9f2cafc469c89b52ea8389e5369~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[A Nobel-Scale Advance: AI-Powered CRISPR Platform to End Infection-Associated Chronic Conditions - Lite]]></title><description><![CDATA[A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS.
It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio-precision]]></description><link>https://www.cynaera.com/post/crispr-remission-lite</link><guid isPermaLink="false">681ce30d2d8811f07a22f76a</guid><category><![CDATA[AI Strategy]]></category><category><![CDATA[Philanthropic Tools]]></category><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[Data Ethics]]></category><category><![CDATA[Public Policy]]></category><category><![CDATA[White Paper]]></category><pubDate>Thu, 08 May 2025 18:10:09 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_d97bd7fed9764cb8a382336c6cadb9ab~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[The Science of Remission: Reversing the Terrain of Infection-Associated Chronic Conditions (IACCs)]]></title><description><![CDATA[Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes.  The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reactivity and trauma.]]></description><link>https://www.cynaera.com/post/the-science-of-iacc-remission</link><guid isPermaLink="false">6813408df547f5de525ecd17</guid><category><![CDATA[Healthcare Innovations]]></category><category><![CDATA[AI Strategy]]></category><category><![CDATA[Public Infrastructure]]></category><category><![CDATA[Data Ethics]]></category><category><![CDATA[Public Policy]]></category><pubDate>Thu, 01 May 2025 20:59:09 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ef8542_ca0d38f709894ee9831da6ff4cc2d8c4~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item></channel></rss>